Inotrem Email Format

Biotechnology ResearchÎle-de-France, France11-50 Employees

Inotrem is a biotechnology company specialized in immunotherapy for acute inflammatory syndromes, such as septic shock.

Founded in 2013, with offices in Paris and a technology center in Nancy (France), the company has developed a new concept of immunomodulation that targets the TREM-1 pathway to control unbalanced inflammatory responses.

Leveraging its proprietary technology platform, Inotrem has developed the first-in-class TREM-1 inhibitor, nangibotide, with applications in a number of therapeutic indications such as septic shock or myocardial infarction. Next to acute inflammatory syndromes, Inotrem is also developing a program targeting chronic inflammatory diseases.

✕

Access Insights for Inotrem and Millions of Other Companies

Sign up for full access to Inotrem information. No credit card needed.

Continue with GoogleContinue with Microsoft

OR

Work email

Create AccountBy creating an account, you agree to LeadIQ's Terms of Use and Privacy Policy.

Sign up for free to view info

Company overview Employee directory